Mephedrone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mephedrone
Accession Number
DB13108
Type
Small Molecule
Groups
Investigational
Description

Mephedrone has been investigated in Alcohol-Related Disorders and Amphetamine-Related Disorders.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
8BA8T27317
CAS number
1189805-46-6
Weight
Average: 177.2429
Monoisotopic: 177.115364107
Chemical Formula
C11H15NO
InChI Key
YELGFTGWJGBAQU-UHFFFAOYSA-N
InChI
InChI=1S/C11H15NO/c1-8-4-6-10(7-5-8)11(13)9(2)12-3/h4-7,9,12H,1-3H3
IUPAC Name
2-(methylamino)-1-(4-methylphenyl)propan-1-one
SMILES
CNC(C)C(=O)C1=CC=C(C)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Mephedrone.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of Mephedrone.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Mephedrone.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Mephedrone.Approved
AcrivastineMephedrone may decrease the sedative activities of Acrivastine.Approved
AlcaftadineMephedrone may decrease the sedative activities of Alcaftadine.Approved
AlfentanilMephedrone may increase the analgesic activities of Alfentanil.Approved, Illicit
AlimemazineMephedrone may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmasilateAlmasilate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved, Experimental
AloglutamolAloglutamol may decrease the excretion rate of Mephedrone which could result in a higher serum level.Experimental
AlphacetylmethadolMephedrone may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineMephedrone may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of Mephedrone.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Mephedrone.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of Mephedrone.Approved
Ammonium chlorideThe serum concentration of Mephedrone can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmoxapineAmoxapine may increase the stimulatory activities of Mephedrone.Approved
AmperozideAmperozide may decrease the stimulatory activities of Mephedrone.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Mephedrone is combined with Amphetamine.Approved, Illicit
AntazolineMephedrone may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Mephedrone.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Mephedrone.Approved
AstemizoleMephedrone may decrease the sedative activities of Astemizole.Approved, Withdrawn
AzaperoneAzaperone may decrease the stimulatory activities of Mephedrone.Investigational, Vet Approved
AzatadineMephedrone may decrease the sedative activities of Azatadine.Approved
AzelastineMephedrone may decrease the sedative activities of Azelastine.Approved
BamipineMephedrone may decrease the sedative activities of Bamipine.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Mephedrone.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Mephedrone.Investigational
BenzatropineMephedrone may decrease the sedative activities of Benzatropine.Approved
BezitramideMephedrone may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Mephedrone.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Experimental
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Mephedrone.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Mephedrone is combined with Brofaromine.Experimental
BromperidolBromperidol may decrease the stimulatory activities of Mephedrone.Investigational
BrompheniramineMephedrone may decrease the sedative activities of Brompheniramine.Approved
BuclizineMephedrone may decrease the sedative activities of Buclizine.Approved
BuprenorphineMephedrone may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of Mephedrone.Experimental
ButorphanolMephedrone may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric AcidMephedrone may decrease the sedative activities of Butyric Acid.Experimental, Investigational
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Experimental
CarbinoxamineMephedrone may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilMephedrone may increase the analgesic activities of Carfentanil.Illicit, Investigational, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Mephedrone.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Mephedrone.Withdrawn
CetirizineMephedrone may decrease the sedative activities of Cetirizine.Approved
ChloropyramineMephedrone may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineMephedrone may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineMephedrone may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Mephedrone.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Mephedrone.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Mephedrone.Approved, Investigational, Withdrawn
CimetidineMephedrone may decrease the sedative activities of Cimetidine.Approved
CinnarizineMephedrone may decrease the sedative activities of Cinnarizine.Approved, Investigational
ClemastineMephedrone may decrease the sedative activities of Clemastine.Approved
ClomipramineClomipramine may increase the stimulatory activities of Mephedrone.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Mephedrone.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Mephedrone.Experimental
ClozapineClozapine may decrease the stimulatory activities of Mephedrone.Approved
CodeineMephedrone may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Mephedrone.Approved
CyclizineMephedrone may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Mephedrone.Approved
CyproheptadineMephedrone may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Mephedrone.Approved
DesipramineDesipramine may increase the stimulatory activities of Mephedrone.Approved
DesloratadineMephedrone may decrease the sedative activities of Desloratadine.Approved, Investigational
DexbrompheniramineMephedrone may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniramineMephedrone may decrease the sedative activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateMephedrone may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideMephedrone may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneMephedrone may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineMephedrone may increase the analgesic activities of Dezocine.Approved, Investigational
DibenzepinDibenzepin may increase the stimulatory activities of Mephedrone.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
DihydrocodeineMephedrone may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineMephedrone may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineMephedrone may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateMephedrone may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneMephedrone may decrease the sedative activities of Dimetindene.Approved, Investigational
DimetotiazineMephedrone may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineMephedrone may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylateMephedrone may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of Mephedrone.Experimental
DosulepinDosulepin may increase the stimulatory activities of Mephedrone.Approved
DoxepinMephedrone may decrease the sedative activities of Doxepin.Approved
DoxylamineMephedrone may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEMephedrone may increase the analgesic activities of DPDPE.Experimental
DroperidolDroperidol may decrease the stimulatory activities of Mephedrone.Approved, Vet Approved
EbastineMephedrone may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Mephedrone.Investigational
EmedastineMephedrone may decrease the sedative activities of Emedastine.Approved
EpinastineMephedrone may decrease the sedative activities of Epinastine.Approved, Investigational
EsmirtazapineMephedrone may decrease the sedative activities of Esmirtazapine.Investigational
EthopropazineMephedrone may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mephedrone.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Withdrawn
EthylmorphineMephedrone may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtorphineMephedrone may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineMephedrone may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Mephedrone.Approved, Illicit, Withdrawn
FentanylMephedrone may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineMephedrone may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of Mephedrone.Experimental
FlunarizineMephedrone may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Mephedrone.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Mephedrone.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Mephedrone.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Mephedrone.Approved, Investigational, Vet Approved
Glutamic AcidThe serum concentration of Mephedrone can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of Mephedrone can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Mephedrone.Approved
HarmalineThe risk or severity of adverse effects can be increased when Mephedrone is combined with Harmaline.Experimental
HeroinMephedrone may increase the analgesic activities of Heroin.Approved, Illicit, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Mephedrone.Experimental
HydrocodoneMephedrone may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneMephedrone may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Mephedrone which could result in a higher serum level.Experimental, Investigational
HydroxyzineMephedrone may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Mephedrone.Approved
ImipramineImipramine may increase the stimulatory activities of Mephedrone.Approved
Ioflupane I-123Mephedrone may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of Mephedrone.Experimental
IproclozideIproclozide may increase the hypertensive activities of Mephedrone.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Mephedrone.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Mephedrone.Approved
IsothipendylMephedrone may decrease the sedative activities of Isothipendyl.Approved
KetobemidoneMephedrone may increase the analgesic activities of Ketobemidone.Approved, Investigational
KetotifenMephedrone may decrease the sedative activities of Ketotifen.Approved
LafutidineMephedrone may decrease the sedative activities of Lafutidine.Investigational
LavoltidineMephedrone may decrease the sedative activities of Lavoltidine.Investigational
LevocabastineMephedrone may decrease the sedative activities of Levocabastine.Approved
LevocetirizineMephedrone may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateMephedrone may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
LevorphanolMephedrone may increase the analgesic activities of Levorphanol.Approved
LithiumLithium may decrease the stimulatory activities of Mephedrone.Approved
LodoxamideMephedrone may decrease the sedative activities of Lodoxamide.Approved
LofentanilMephedrone may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of Mephedrone.Experimental
LoratadineMephedrone may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of Mephedrone.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Mephedrone.Approved
MagaldrateMagaldrate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Mephedrone.Withdrawn
MeclizineMephedrone may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of Mephedrone.Approved, Investigational
MeptazinolMephedrone may increase the analgesic activities of Meptazinol.Experimental
MepyramineMephedrone may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineMephedrone may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Mephedrone.Approved, Investigational
MethadoneMephedrone may increase the analgesic activities of Methadone.Approved
Methadyl AcetateMephedrone may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethapyrileneMephedrone may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
MethenamineThe serum concentration of Mephedrone can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Mephedrone.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Mephedrone.Approved, Investigational
MetiamideMephedrone may decrease the sedative activities of Metiamide.Experimental
MianserinMephedrone may decrease the sedative activities of Mianserin.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Mephedrone.Approved
MirtazapineMephedrone may decrease the sedative activities of Mirtazapine.Approved
MizolastineMephedrone may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Mephedrone.Approved
MolindoneMolindone may decrease the stimulatory activities of Mephedrone.Approved
MoperoneMoperone may decrease the stimulatory activities of Mephedrone.Experimental
MorphineMephedrone may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Mephedrone.Experimental
NalbuphineMephedrone may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of Mephedrone.Withdrawn
NicomorphineMephedrone may increase the analgesic activities of Nicomorphine.Experimental
NizatidineMephedrone may decrease the sedative activities of Nizatidine.Approved
NormethadoneMephedrone may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of Mephedrone.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Mephedrone.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Mephedrone.Approved, Investigational
OlopatadineMephedrone may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Mephedrone.Approved
OpipramolOpipramol may increase the stimulatory activities of Mephedrone.Investigational
OpiumMephedrone may increase the analgesic activities of Opium.Approved, Illicit
OsanetantOsanetant may decrease the stimulatory activities of Mephedrone.Investigational
OxatomideMephedrone may decrease the sedative activities of Oxatomide.Investigational
OxycodoneMephedrone may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneMephedrone may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Mephedrone.Experimental
OzagrelMephedrone may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of Mephedrone.Approved
PargylinePargyline may increase the hypertensive activities of Mephedrone.Approved
PemirolastMephedrone may decrease the sedative activities of Pemirolast.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of Mephedrone.Experimental
PentazocineMephedrone may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Mephedrone.Investigational
PerospironePerospirone may decrease the stimulatory activities of Mephedrone.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Mephedrone.Approved
PethidineMephedrone may increase the analgesic activities of Pethidine.Approved
PhenazocineMephedrone may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Mephedrone.Approved
PhenindamineMephedrone may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Mephedrone.Withdrawn
PheniramineMephedrone may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Mephedrone.Approved
PhenoperidineMephedrone may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Mephedrone.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Mephedrone.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Mephedrone.Approved
PipamperonePipamperone may decrease the stimulatory activities of Mephedrone.Approved, Investigational
PipotiazinePipotiazine may decrease the stimulatory activities of Mephedrone.Approved, Investigational
PiritramideMephedrone may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Mephedrone.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Mephedrone.Withdrawn
ProcarbazineThe risk or severity of adverse effects can be increased when Mephedrone is combined with Procarbazine.Approved
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Mephedrone.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Mephedrone.Approved, Vet Approved
PromethazineMephedrone may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Mephedrone.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Mephedrone.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Mephedrone.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Mephedrone.Approved
QuifenadineMephedrone may decrease the sedative activities of Quifenadine.Experimental
RacloprideRaclopride may decrease the stimulatory activities of Mephedrone.Investigational
RanitidineMephedrone may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Mephedrone.Approved
RemifentanilMephedrone may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Mephedrone.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Mephedrone.Approved, Investigational
RisperidoneRisperidone may decrease the stimulatory activities of Mephedrone.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Mephedrone.Investigational
Roxatidine acetateMephedrone may decrease the sedative activities of Roxatidine acetate.Approved, Investigational
SafrazineSafrazine may increase the hypertensive activities of Mephedrone.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Mephedrone is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Mephedrone.Approved, Investigational, Withdrawn
Sodium bicarbonateSodium bicarbonate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
SufentanilMephedrone may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Mephedrone.Approved, Investigational
SultoprideSultopride may decrease the stimulatory activities of Mephedrone.Experimental
TapentadolMephedrone may increase the analgesic activities of Tapentadol.Approved
TerfenadineMephedrone may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifeneMephedrone may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Mephedrone.Investigational
ThiopropazateThiopropazate may decrease the stimulatory activities of Mephedrone.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Mephedrone.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Mephedrone.Approved, Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Mephedrone.Approved
ThonzylamineMephedrone may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Mephedrone.Approved, Investigational
TiaprideTiapride may decrease the stimulatory activities of Mephedrone.Approved, Investigational
TilidineMephedrone may increase the analgesic activities of Tilidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Mephedrone.Approved
TramadolMephedrone may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastMephedrone may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Mephedrone.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Mephedrone.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Mephedrone.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of Mephedrone.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Mephedrone.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of Mephedrone.Approved
TripelennamineMephedrone may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineMephedrone may decrease the sedative activities of Triprolidine.Approved
TritoqualineMephedrone may decrease the sedative activities of Tritoqualine.Experimental
TromethamineTromethamine may decrease the excretion rate of Mephedrone which could result in a higher serum level.Approved
VeraliprideVeralipride may decrease the stimulatory activities of Mephedrone.Experimental
Vitamin CThe serum concentration of Mephedrone can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of Mephedrone.Approved
ZotepineZotepine may decrease the stimulatory activities of Mephedrone.Approved, Investigational
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Mephedrone.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB41923
PubChem Compound
45266826
PubChem Substance
347829232
ChemSpider
21485694
ChEBI
59331

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAlcohol-Related Disorders / Amphetamine-Related Disorders1
1CompletedNot AvailableAmphetamine-Related Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.715 mg/mLALOGPS
logP1.33ALOGPS
logP2.12ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)18.66ChemAxon
pKa (Strongest Basic)8.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.1 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.13 m3·mol-1ChemAxon
Polarizability20.66 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ot-0900000000-63a56a651f789a893e55
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-72c24c862242c481aca4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-c5357ff91e06cdd98e2f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-a293b8fd331ba92afc2b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-ab08f3ff9c43c678a409
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01ot-0900000000-0e8d2be244e2c2b90065
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-c36f9c805707cdca4596
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0005-0900000000-0a4988d65ddec4e44b3d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-03bb00bf907535516e3d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-692e09986df677e5ecc1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-33cea69ee5f543869c02
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01ot-0900000000-888d4a226b1d533a2ea2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-5717c7c0504ffa0c6054
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0005-0900000000-f4e14927b85bb7d9e5b4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-3fd3aa739f1f8f082f8d

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenylpropanes / Benzoyl derivatives / Aryl alkyl ketones / Toluenes / Alpha-amino ketones / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Alkyl-phenylketone / Phenylpropane / Benzoyl / Aryl alkyl ketone / Toluene / Monocyclic benzene moiety / Benzenoid / Alpha-aminoketone / Secondary aliphatic amine / Secondary amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
amphetamines, propanone (CHEBI:59331)

Drug created on October 20, 2016 21:13 / Updated on November 09, 2017 05:18